[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)

When Ozempic activates those receptors, it slows motility from the stomach all the way down to the large intestine
Clinical trials have shown that when combined with lifestyle modifications, GLP-1 medications can help suitable patients achieve meaningful and sustained weight loss
More choice on the platform is the best thing for customers everywhere. Hims & Hers stock whipsawed on Thursday morning, jumping more than 13% to $27.55 when the news was announced and then settling back down to $24.41 in late morning trading
In aging canine models, these pathways are particularly relevant because senior dogs exhibit reduced tissue perfusion, slower fibroblast response, and diminished collagen synthesis all areas where BPC-157s documented mechanisms intersect directly
Moreover, the combined treatment of sDPP4 and LPS leads to increased expression and secretion of the pro-inflammatory cytokines, TNF and IL-6